Biagio Ricciuti: Discussing immunotherapy and targeted therapy for KRAS + NSCLC
Biagio Ricciuti, thoracic oncologist at the Dana-Farber Cancer Institute, shared a post on X by Xiuning Le, the Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, adding:
“Had a great time at MaTOS24 discussing immunotherapy and targeted therapy for KRAS+ NSCLC. Grateful for the insightful perspectives from stellar panelists and friends.”
Quoting Xiuning Le’s post below:
“Wrapping up MaTOS24 in beautiful Lake Tahoe. I discussed a pt case with EGFR compound PACC mutation with liver and CNS mets. Fun to see the debate with Ferdinandos Skoulidis, Biagio Ricciuti (of course on KRAS) and hang out with Boston oncology girls Zosia Piotrowska, Jessica J Lin, Julia Rotow, Elaine Shum.”
Biagio Ricciuti is a thoracic oncologist at the Dana-Farber Cancer Institute. His research interests are various aspects of lung cancer, including novel therapeutics, biomarker identification, and predictive modeling for patient outcomes. Besides being actively engaged in research, Dr. Ricciuti is involved in clinical trials and patient care.
Xiuning Le, MD, serves as the Deputy Section Chief of Thoracic Medical Oncology at MD Anderson Cancer Center, where she oversees clinical research, including strategic planning and the operation of clinical trials within the department. She is also an Associate Professor and a leading translational researcher, specializing in resistance mechanisms, cancer genetics and genomics, biomarkers, and radiomics.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023